Regulatory FDA hands another rejection to Replimune’s melanoma therapy PharmaphorumReplimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses. RegulatoryOncologyRead full story Post navigation Previous: Bayer wins MHRA approval for Kerendia in heart failureNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026